Literature DB >> 15284266

Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy.

M Jacob Adams1, Stuart R Lipsitz, Steven D Colan, Nancy J Tarbell, S Ted Treves, Lisa Diller, Nina Greenbaum, Peter Mauch, Steven E Lipshultz.   

Abstract

PURPOSE: Cardiovascular status was assessed in 48 Hodgkin's disease (HD) survivors at a median of 14.3 years (range, 5.9 to 27.5 years) after diagnosis because they may be at increased risk for cardiovascular abnormalities. PATIENTS AND METHODS: Patients completed the Short-Form 36 quality-of-life instrument and were screened by echocardiography, exercise stress testing, and resting and 24-hour ECG.
RESULTS: All patients received mediastinal irradiation (median, 40.0 Gy; range, 27.0 to 51.7 Gy) at a median age of 16.5 years (range, 6.4 to 25.0 years). Four patients received an anthracycline. Although every patient described their health as good or better, and none had symptomatic heart disease at screening, all but one had cardiac abnormalities on screening. Restrictive cardiomyopathy was suggested by reduced average left ventricular (LV) dimension (P < .001) and mass (P < .001), without increased LV wall thickness. Significant valvular defects were present in 42%; 75% had conduction defects. One survivor developed complete heart block shortly after the study visit. Autonomic dysfunction was suggested by a monotonous heart rate in 57%, persistent tachycardia in 31%, and blunted hemodynamic responses to exercise in 27%. Peak oxygen uptake (VO2max) during exercise, a predictor of mortality in heart failure, was significantly reduced (< 20 mL/kg/m2) in 30% of survivors. VO2max was correlated with increasing fatigue, increasing shortness of breath (both, r = -0.35; P =. 02), and decreasing physical component score on the SF-36 (r = 0.554; P = .00017).
CONCLUSION: A variety of unsuspected, clinically significant cardiovascular abnormalities are common in long-term survivors of HD who are treated at a young age with mediastinal irradiation. We recommend serial, comprehensive cardiac screening of HD survivors who fit this profile. Copyright 2004 American Society of Clinical Onocology

Entities:  

Mesh:

Year:  2004        PMID: 15284266     DOI: 10.1200/JCO.2004.09.109

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  123 in total

Review 1.  Experimental radiation-induced heart disease: past, present, and future.

Authors:  Marjan Boerma
Journal:  Radiat Res       Date:  2012-06-04       Impact factor: 2.841

Review 2.  State-of-the-art issues in Hodgkin's lymphoma survivorship.

Authors:  Shrujal S Baxi; Matthew J Matasar
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 3.  Late effects of therapy for Hodgkin's lymphoma.

Authors:  Michael Jacob Adams; Louis S Constine; Steven E Lipshultz
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

Review 4.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

5.  Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study.

Authors:  David C Landy; Tracie L Miller; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M K Rovitelli; M Jacob Adams; Steven E Lipshultz
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

6.  Characteristics and determinants of adiposity in pediatric cancer survivors.

Authors:  Tracie L Miller; Stuart R Lipsitz; Gabriela Lopez-Mitnik; Andrea S Hinkle; Louis S Constine; M Jacob Adams; Carol French; Cynthia Proukou; Amy Rovitelli; Steven E Lipshultz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 7.  Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training.

Authors:  Anthony F Yu; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

8.  Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Authors:  Jan Kriz; Max Spickermann; Philipp Lehrich; Heinz Schmidberger; Gabriele Reinartz; Hans Eich; Uwe Haverkamp
Journal:  Strahlenther Onkol       Date:  2015-04-16       Impact factor: 3.621

9.  Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Sharon M Castellino; Ann M Geiger; Ann C Mertens; Wendy M Leisenring; Janet A Tooze; Pam Goodman; Marilyn Stovall; Leslie L Robison; Melissa M Hudson
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

10.  Cancer survivorship: the concept and the increasingly recognized reality.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.